lebrikizumab-lbkz
CHEBI:CHEBI_749456
Drug Classification
-
chemical entityView Class →
CHEBI:24431
Important Medical Information
⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.
- Always consult with a healthcare professional before starting, stopping, or modifying any medication.
- Side effects may vary and this list may not be comprehensive.
- Drug interactions may occur with other medications.
Additional Identifiers
🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.
Additional Attributes
- product_type
- HUMAN PRESCRIPTION DRUG
- listing_expiration_date
- 20251231
- marketing_start_date
- 20240913
- package_marketing_start_date
- 20240913
- dosage_form
- INJECTION, SOLUTION
- route
- SUBCUTANEOUS
- marketing_category
- BLA
- labeler_name
- Eli Lilly and Company
- manufacturer_name
- Eli Lilly and Company
- active_ingredient_name
- LEBRIKIZUMAB
- generic_name
- lebrikizumab-lbkz
- brand_name
- EBGLYSS
- brand_name_base
- EBGLYSS
- product_ndc
- 0002-7797
- application_number
- BLA761306
- spl_id
- 62d64e86-63ab-4ac7-9823-63d5f73ade45
- active_ingredient_strength
- 250 mg/2mL
- package_ndc
- 0002-7797-61
- package_description
- 1 SYRINGE in 1 CARTON (0002-7797-61) / 1 mL in 1 SYRINGE
- rxcui
- 2693907
- unii
- U9JLP7V031
- spl_set_id
- 7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5f
- nui
- N0000193986
- pharm_class_epc
- Interleukin-13 Antagonist [EPC]
- pharm_class_moa
- Interleukin-13 Antagonists [MoA]
- 22-rdf-syntax-ns#type
- http://www.w3.org/2002/07/owl#Class